These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 23802291)

  • 21. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.
    Washburn WN
    Expert Opin Ther Pat; 2009 Nov; 19(11):1485-99. PubMed ID: 19852718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Lv B; Feng Y; Dong J; Xu M; Xu B; Zhang W; Sheng Z; Welihinda A; Seed B; Chen Y
    ChemMedChem; 2010 Jun; 5(6):827-31. PubMed ID: 20414917
    [No Abstract]   [Full Text] [Related]  

  • 23. Renal glucose reabsorption inhibitors to treat diabetes.
    Bailey CJ
    Trends Pharmacol Sci; 2011 Feb; 32(2):63-71. PubMed ID: 21211857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
    Grempler R; Thomas L; Eckhardt M; Himmelsbach F; Sauer A; Sharp DE; Bakker RA; Mark M; Klein T; Eickelmann P
    Diabetes Obes Metab; 2012 Jan; 14(1):83-90. PubMed ID: 21985634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of SGLT2: a novel strategy for treatment of type 2 diabetes mellitus.
    Pfister M; Whaley JM; Zhang L; List JF
    Clin Pharmacol Ther; 2011 Apr; 89(4):621-5. PubMed ID: 21346749
    [No Abstract]   [Full Text] [Related]  

  • 26. Indole-glucosides as novel sodium glucose co-transporter 2 (SGLT2) inhibitors. Part 2.
    Zhang X; Urbanski M; Patel M; Cox GG; Zeck RE; Bian H; Conway BR; Beavers MP; Rybczynski PJ; Demarest KT
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1696-701. PubMed ID: 16380256
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Canagliflozin.
    Rodríguez-Gutiérrez R; Gonzalez-Saldivar G
    Cleve Clin J Med; 2014 Feb; 81(2):87-8. PubMed ID: 24493488
    [No Abstract]   [Full Text] [Related]  

  • 28. Canagliflozin.
    Keller DL
    Cleve Clin J Med; 2014 Feb; 81(2):88-90. PubMed ID: 24493489
    [No Abstract]   [Full Text] [Related]  

  • 29. In reply.
    Vouyiouklis M
    Cleve Clin J Med; 2014 Feb; 81(2):90. PubMed ID: 24493490
    [No Abstract]   [Full Text] [Related]  

  • 30. Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
    Goodwin NC; Mabon R; Harrison BA; Shadoan MK; Almstead ZY; Xie Y; Healy J; Buhring LM; DaCosta CM; Bardenhagen J; Mseeh F; Liu Q; Nouraldeen A; Wilson AG; Kimball SD; Powell DR; Rawlins DB
    J Med Chem; 2009 Oct; 52(20):6201-4. PubMed ID: 19785435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
    Ellsworth BA; Meng W; Patel M; Girotra RN; Wu G; Sher PM; Hagan DL; Obermeier MT; Humphreys WG; Robertson JG; Wang A; Han S; Waldron TL; Morgan NN; Whaley JM; Washburn WN
    Bioorg Med Chem Lett; 2008 Sep; 18(17):4770-3. PubMed ID: 18707880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trial watch: SGLT2 inhibitor shows promise in type 2 diabetes.
    Nat Rev Drug Discov; 2010 Mar; 9(3):182. PubMed ID: 20190779
    [No Abstract]   [Full Text] [Related]  

  • 33. Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.
    Yao CH; Song JS; Chen CT; Yeh TK; Hung MS; Chang CC; Liu YW; Yuan MC; Hsieh CJ; Huang CY; Wang MH; Chiu CH; Hsieh TC; Wu SH; Hsiao WC; Chu KF; Tsai CH; Chao YS; Lee JC
    J Med Chem; 2011 Jan; 54(1):166-78. PubMed ID: 21128592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibiting renal sodium-glucose transport in diabetes: pass the salt.
    Zietse R; Hoorn EJ
    Kidney Int; 2009 Dec; 76(12):1293; author reply 1293. PubMed ID: 19946314
    [No Abstract]   [Full Text] [Related]  

  • 35. O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors.
    Xu B; Lv B; Feng Y; Xu G; Du J; Welihinda A; Sheng Z; Seed B; Chen Y
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5632-5. PubMed ID: 19700318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence of promising therapies in diabetes mellitus.
    Akkati S; Sam KG; Tungha G
    J Clin Pharmacol; 2011 Jun; 51(6):796-804. PubMed ID: 20705952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diabetes management at the end of life #258.
    Jeffreys E; Rosielle DA
    J Palliat Med; 2012 Oct; 15(10):1152-4. PubMed ID: 22957680
    [No Abstract]   [Full Text] [Related]  

  • 38. The authors reply.
    Kohan DE; Fioretto P; Tang W; List JF
    Kidney Int; 2014 Dec; 86(6):1272. PubMed ID: 25427094
    [No Abstract]   [Full Text] [Related]  

  • 39. Chromium decreases blood glucose in a patient with diabetes.
    Littlefield D
    J Am Diet Assoc; 1994 Dec; 94(12):1368. PubMed ID: 7963183
    [No Abstract]   [Full Text] [Related]  

  • 40. SGLT inhibitors in management of diabetes.
    Tahrani AA; Barnett AH; Bailey CJ
    Lancet Diabetes Endocrinol; 2013 Oct; 1(2):140-51. PubMed ID: 24622320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.